Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin.
Life Sci
; 71(26): 3109-19, 2002 Nov 15.
Article
em En
| MEDLINE
| ID: mdl-12408877
ABSTRACT
The effect of a chronic treatment with low oral doses of verapamil, a calcium channel blocker commonly employed in cardiovascular therapy, on doxorubicin toxicity, was evaluated in CD1 mice. Verapamil, administered at a dosage corresponding to a typical cardiovascular posology in humans, significantly increased doxorubicin toxicity. In particular the mortality was significantly higher and earlier and histological analysis revealed an increase in the severity of lesions in the liver, kidney and small bowel of verapamil pretreated animals. The pharmacokinetic profiles revealed that verapamil treated group had higher doxorubicin peak plasma and tissue levels and AUCs. This study shows that verapamil, administered at low doses, dramatically increases doxorubicin toxicity, probably through an interaction between the two drugs, both P-glycoprotein substrates, on the protein expressed in normal tissues, and suggests caution in the use of the calcium channel blocker for cardiovascular pathologies in patients who have to be treated with antineoplastic agents, substrates of P-glycoprotein.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Bloqueadores dos Canais de Cálcio
/
Verapamil
/
Doxorrubicina
/
Antibióticos Antineoplásicos
Limite:
Animals
Idioma:
En
Revista:
Life Sci
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Itália